UroGen Pharma Ltd.

URGN· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$38.59+0.92%

2026-08-03

Financials

Valuation Metrics

UroGen Pharma Ltd.'s Market Cap is $1.88B. At end of 2025 it was $1.15B. Ranked #2096 of 3,112 in US market (top 67%), #809 of 1,445 on NASDAQ (top 56%), #142 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 53%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$1.88B	US#2,096/3,112 Sec#142/269
Revenue	$140M	US#2,742/3,112 Sec#120/269
Net Income	$-133M	US—/3,112 Sec—/269
Total Assets	$254M	US#2,940/3,112 Sec#232/269
Net Assets	$26M	US#2,971/3,112 Sec#252/269
Value
P/B	73.69x	US#2,949/3,112 Sec#255/269
P/S	13.38x	US#2,732/3,112 Sec#129/269
FCF Yield	-8.83%	US—/3,112 Sec—/269
Profitability
ROA	-52.51%	US#2,976/3,112 Sec#223/269
Op. Margin	-77.02%	US#2,802/3,112 Sec#117/269
Revenue Growth	151.60%	US#93/3,112 Sec#26/269
Financial Health
Debt Ratio	1481.26%	US#2,863/3,112 Sec#255/269
Total Debt	$197M	US#2,196/3,112 Sec#95/269
FCF	$-166M	US#2,697/3,112 Sec#197/269
Cash	$111M	US#2,159/3,112 Sec#171/269
Current Ratio	4.69x	US#513/3,112 Sec#155/269
Performance
1Y Return	98.92%	US#341/3,112 Sec#85/269
1M Return	1.50%	US#1,432/3,112 Sec#59/269
From 52W High	-12.16%	US#1,202/3,112 Sec#68/269
1Y MDD	-42.22%	US#2,058/3,112 Sec#151/269
Trading
Volume	949,134 shares	US#1,528/3,112 Sec#149/269
Trading Value	$36M	US#1,595/3,112 Sec#106/269
Per Share
EPS	$-3.12	US—/3,112 Sec—/269